Vildagliptin more effectively achieves a composite endpoint of HbA1c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment

Vildagliptin more effectively achieves a composite endpoint of HbA1c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment

Abstract This post hoc analysis reports that overall proportion of patients achieving a composite endpoint of HbA1c < 7.0% (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes research and clinical practice 2013-06, Vol.100 (3), p.e78-e81
Hauptverfasser: Bader, Giovanni, Geransar, Parnia, Schweizer, Anja
Format: Artikel
Sprache:eng
Schlagworte:
Adamantane - analogs & derivatives
Adamantane - therapeutic use
Aged
Composite endpoint
Dipeptidyl peptidase-4 (DPP-4) inhibitors
Endocrinology & Metabolism
Female
Glycated Hemoglobin A - metabolism
Humans
Hypoglycemia - drug therapy
Hypoglycemic Agents - therapeutic use
Incretin-based therapy
Male
Metformin - therapeutic use
Middle Aged
Nitriles - therapeutic use
Pyrrolidines - therapeutic use
Sulfonylurea Compounds - therapeutic use
Type 2 diabetes (T2D)
Vildagliptin
Weight Gain - drug effects
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract This post hoc analysis reports that overall proportion of patients achieving a composite endpoint of HbA1c < 7.0% (
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2013.03.011